Chemomab Therapeutics Ltd.CMMB
Price (close)
$2.16
Market cap
$15.8M
P/E
—
Revenue (FY)
—
Net income
-$9.0M
Dividend yield
—
1-year total return
-13.6%
Net margin
—
Revenue growth
—
Debt / equity
—
What Chemomab Therapeutics Ltd. does.
and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs. Based on the unique and pivotal
role of the soluble protein CCL24 in promoting fibrosis and inflammation, we have developed nebokitug, a monoclonal antibody designed
to bind and block CCL24 activity. Nebokitug has demonstrated the potential to treat multiple severe and life-threatening fibrotic
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$6.0M | -$12.5M | -$27.6M | -$24.2M | -$13.9M | -$9.0M |
| Free cash flow | -$5.3M | -$12.6M | -$20.4M | -$23.6M | -$15.4M | -$11.1M |
More on CMMB.
- Chemomab Therapeutics Ltd. summary
- Chemomab Therapeutics Ltd. financial statements
- Chemomab Therapeutics Ltd. key metrics
- Chemomab Therapeutics Ltd. health scores and style box
- Chemomab Therapeutics Ltd. earnings
- Chemomab Therapeutics Ltd. dividends
- Chemomab Therapeutics Ltd. valuation
- Chemomab Therapeutics Ltd. ownership and insiders
- Chemomab Therapeutics Ltd. peers
Figures from Chemomab Therapeutics Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.